The relationships of plasma adiponectin with a favorable lipid profile, decreased inflammation, and less ectopic fat accumulation depend on adiposity

被引:70
作者
Kantartzis, Konstantinos
Rittig, Killian
Balletshofer, Bernd
Machann, Juergen
Schick, Fritz
Porubska, Katarina
Fritsche, Andreas
Haering, Hans-Ulrich
Stefan, Norbert
机构
[1] Univ Tubingen, Dept Internal Med, Div Endocrinol Metab Pathobiochem & Clin Chem, D-72076 Tubingen, Germany
[2] Univ Tubingen, Dept Diagnost Radiol, Tubingen, Germany
[3] Univ Tubingen, Sect Expt Radiol, Tubingen, Germany
关键词
D O I
10.1373/clinchem.2006.067397
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: The metabolic effects of adiponectin, including insulin sensitivity, seem to become stronger with increasing adiposity. Adiposity may also affect the relationship of adiponectin concentrations with serum lipid profile; markers of inflammation, atherosclerosis, and endothelial function; and ectopic fat accumulation. Methods: We measured plasma adiponectin concentrations, serum lipids, and serum markers of inflammation, atherosclerosis, and endothelial function in 242 Caucasians without type 2 diabetes. We also measured visceral adipose tissue with magnetic resonance tomography and liver and intramyocellular fat with H-1 magnetic resonance spectroscopy. Results: We divided the study participants into 2 groups: lean [mean (SE) total body fat, 26% (0.6%); n = 119] and obese [36% (0.6%); n = 123]. In the obese group, plasma adiporiectin concentrations showed a strong positive association with concentrations of HDL cholesterol (P < 0.0001) and negative, associations with LDL cholesterol, triglycerides, high-sensitivity C-reactive protein, interleukin 6, apolipoprotein 13,00, soluble E-selectin, soluble vascular cellular adhesion molecule 1, plasminogen activator inhibitor 1, leukocyte count, and liver and intramyocellular fat (all P < 0.03). In the lean group, adiponectin showed a less strong association With HDL cholesterol (P = 0.005) and liver fat (P = 0.03) and no significant associations with the other variables (all P > 0.10). High visceral adipose tissue was a strong predictor of low adiponectin concentrations, particularly in the obese group, and attenuated many of the significant relationships. Conclusions: High adiponectin plasma concentrations are associated with favorable lipid profiles, decreased subclinical inflammation, decreased markers of atherosclerosis and endothelial function, and low ectopic fat accumulation, particularly in obese persons. Adiponectin may also have a concentration-related effect on the relationship between visceral adipose tissue and these metabolic characteristics, especially in obese persons. (c) 2006 American Association for Clinical Chemistry.
引用
收藏
页码:1934 / 1942
页数:9
相关论文
共 43 条
[1]   Adiponectin relationship with lipid metabolism is independent of body fat mass:: Evidence from both cross-sectional and intervention studies [J].
Baratta, R ;
Amato, S ;
Degano, C ;
Farina, MG ;
Patanè, G ;
Vigneri, R ;
Frittitta, L .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (06) :2665-2671
[2]   Adiponectin and other adipocytokines as predictors of markers of triglyceride-rich lipoprotein metabolism [J].
Chan, DC ;
Watts, GF ;
Ng, TWK ;
Uchida, Y ;
Sakai, N ;
Yamashita, S ;
Barrett, PHR .
CLINICAL CHEMISTRY, 2005, 51 (03) :578-585
[3]   Adiponectin: More than just another fat cell hormone? [J].
Chandran, M ;
Phillips, SA ;
Ciaraldi, T ;
Henry, RR .
DIABETES CARE, 2003, 26 (08) :2442-2450
[4]   Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex [J].
Cnop, M ;
Havel, PJ ;
Utzschneider, KM ;
Carr, DB ;
Sinha, MK ;
Boyko, EJ ;
Retzlaff, BM ;
Knopp, RH ;
Brunzell, JD ;
Kahn, SE .
DIABETOLOGIA, 2003, 46 (04) :459-469
[5]   Adiponectinemia in visceral obesity:: Impact on glucose tolerance and plasma lipoprotein and lipid levels in men [J].
Côté, M ;
Mauriège, P ;
Bergeron, J ;
Alméras, N ;
Tremblay, A ;
Lemieux, I ;
Després, JP .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (03) :1434-1439
[6]   Hepatic lipase and dyslipidemia: interactions among genetic variants, obesity, gender, and diet [J].
Deeb, SS ;
Zambon, A ;
Carr, MC ;
Ayyobi, AF ;
Brunzell, JD .
JOURNAL OF LIPID RESEARCH, 2003, 44 (07) :1279-1286
[7]   Contribution of CB1 blockade to the management of high-risk abdominal obesity [J].
Després, JP ;
Lemieux, I ;
Alméras, N .
INTERNATIONAL JOURNAL OF OBESITY, 2006, 30 (Suppl 1) :S44-S52
[8]   Overexpression of hepatic lipase in transgenic mice decreases apolipoprotein B-containing and high density lipoproteins. Evidence that hepatic lipase acts as a ligand for lipoprotein uptake [J].
Dichek, HL ;
Brecht, W ;
Fan, JL ;
Ji, ZS ;
McCormick, SPA ;
Akeefe, H ;
Conzo, L ;
Sanan, DA ;
Weisgraber, KH ;
Young, SG ;
Taylor, JM ;
Mahley, RW .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (04) :1896-1903
[9]   Association between adiponectin and mediators of inflammation in obese women [J].
Engeli, S ;
Feldpausch, M ;
Gorzelniak, K ;
Hartwig, F ;
Heintze, U ;
Janke, J ;
Möhlig, M ;
Pfeiffer, AFH ;
Luft, FC ;
Sharma, AM .
DIABETES, 2003, 52 (04) :942-947
[10]  
EXLEY A R, 1990, Cytokine, V2, P353, DOI 10.1016/1043-4666(90)90065-2